ReviewCureus2026
Psoriasis and Psoriatic Arthritis in Pregnancy: Current Evidence and Clinical Considerations.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis and psoriatic arthritis (PsA) are chronic, immune-mediated inflammatory diseases that commonly affect individuals of reproductive age, presenting unique challenges relating to fertility, pregnancy, lactation, and long-term reproductive health. This narrative review summarizes the current evidence on the relationship between psoriatic diseases and pregnancy, focusing particularly on disease activity, fertility, obstetric outcomes, hereditary risk, the psychosocial impact, and treatment options throughout the reproductive journey. The available evidence indicates that psoriasis and PsA can impact reproductive health and fertility, as well as pregnancy outcomes, particularly in individuals with active or severe disease. Chronic systemic inflammation and associated comorbidities likely play an important role in these associations. While pregnancy-related immunological adaptations may improve disease activity in some women, flare-ups remain common during the postpartum period. The management of psoriatic disease during pregnancy has undergone a substantial paradigm shift. Contemporary evidence increasingly supports maintaining adequate disease control throughout the reproductive period with therapies with an established safety profile. This review highlights the evolving understanding of psoriasis and PsA as systemic diseases that extend beyond dermatological and rheumatological manifestations and may influence reproductive health at multiple levels. Future research should focus on the long-term safety of newer targeted therapies, the impact of paternal exposure, patient-reported reproductive outcomes, and developing evidence-based, multidisciplinary care pathways for women with psoriatic disease during pregnancy and the postpartum period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.